Background: One of the common Mutravaha Srotas diseases listed in Ayurveda is Mutrakricchra, which is characterized by discomfort, burning, and difficulty during micturition. It can be associated with a simple urinary tract infection (UTI) based on its clinical signs. With its Mutrala, Pittashamaka, Shothahara, and Rasayana qualities, Amritadi Kwath, a traditional Ayurvedic formulation mentioned in Chakradatta, is a possible therapeutic intervention for the treatment of Mutrakricchra. Objective: To evaluate the clinical efficacy of Amritadi Kwath in the management of Mutrakricchra with special reference to UTI. Materials and Methods: Thirty patients with a diagnosis of Mutrakricchra, ages 20 to 60, participated in an open-label, prospective, single-arm clinical research. For thirty days, Amritadi Kwath was given to each participant. Both objective (urine color and pus cells) and subjective (burning micturition, frequency of micturition, and discomfort during micturition) measures were used to evaluate clinical efficacy. The paired-sample t-test was used for statistical analysis. Results: All evaluated indicators showed statistically substantial improvement (p < 0.001) after treatment with Amritadi Kwath. Following treatment, there were notable decreases in burning micturition, frequency of urination, discomfort during micturition, urinary pus cells, and aberrant urine colour. Conclusion: In the treatment of Mutrakricchra, Amritadi Kwath showed notable clinical success, particularly with regard to urinary tract infections. Without any known side effects, the mixture successfully reduced urinary symptoms and enhanced laboratory parameters, indicating that it is a safe, efficient, and cost-effective Ayurvedic remedy. To confirm these results, more multicentric research with bigger sample sizes and longer follow-up is advised.

Background: Darunaka is a common scalp disorder. Priyalbeejadi Lepa was assessed for its role in managing Darunaka. Objective: The study was planned to evaluate the efficacy of Priyalbeejadi Lepa in the management of Darunaka. Methods: The study included forty patients of both sexes, aged 16 to 40, who met Darunaka's diagnostic criteria and were seen in the institute's outpatient department. They were split up at random, with Aamrabeeja Haritaki Lepa administered on alternate days for 30 days to the Controlled Group and Priyalbeejadi Lepa to the Interventional Group. Twakasphutana, Kandu, Keshachyuti, Rookshata, and Adherent Scalp Flaking Score (ASFS) were evaluated. On days 15, 30, and 45, clinical evaluations were conducted. Effect sizes were computed using paired t-tests for within-group comparisons and independent t-tests for between-group comparisons. Results: Following treatment, all clinical metrics significantly improved for both groups (p < 0.01). Twakasphutana demonstrated a statistically significant advantage over the control group (p = 0.044, Cohen's d = 0.66), however the Interventional Group consistently showed larger decreases in mean scores across parameters. Other measures had small to medium effect sizes that favored the Interventional Group and showed gains that were clinically significant. Conclusion: With notable improvements in scalp flaking, itching, and related clinical symptoms, Priyalbeejadi Lepa is a successful intervention for Darunaka. When compared to Aamrabeeja Haritaki Lepa, it had better therapeutic results, indicating its potential as a preferred therapy option.